Cabozantinib (BMS-907351)

For research use only. Not for use in humans.

目录号：S1119 别名： XL184 中文名称：卡博替尼

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351)是一种有效的VEGFR2抑制剂，在无细胞试验中IC50为0.035 nM，也能有效抑制c-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXL，IC50分别为1.3 nM，4 nM，4.6 nM，12 nM/11.3 nM/6 nM，14.3 nM 和 7 nM。Cabozantinib 在结肠癌细胞中可通过AKT/GSK-3β/NF-κB信号通路诱导PUMA依赖的凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1800.41	现货
5mg	RMB 902.82	现货
10mg	RMB 1393.37	现货
50mg	RMB 3837.48	现货
200mg	RMB 8176.22	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cabozantinib (BMS-907351)发表文献83篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Discov, 2018, 8(7):836-849

PubMed: 29657135 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2124

PubMed: 32358507 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1610.2020

PubMed: 33148676 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3816

PubMed: 33348809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2838

PubMed: 33019652 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1401

PubMed: 32485915 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Mol Cancer Res, 2020, 27;molcanres.1245.2019

PubMed: 32461304 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.047779

PubMed: 33318047 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )
Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Commun Biol, 2020, 3(1):776

PubMed: 33328556 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Life Sci, 2020, 247:117402

PubMed: 32035930 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(6):830-844

PubMed: 30929576 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1991-2001

PubMed: 30848481 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):43

PubMed: 30898150 ( click the link to review the publication )

Cell Death Dis, 2019, 10(3):201

PubMed: 30814510 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0043

PubMed: 31527225 ( click the link to review the publication )

Oncogenesis, 2019, 8(2):7

PubMed: 30647407 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(9)

PubMed: 31027376 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019,

PubMed: 30863492 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4821

PubMed: 30446652 ( click the link to review the publication )
Sci Rep, 2018, 8(1):4177

PubMed: 29520051 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Regen Eng Transl Med, 2018, 4(3):120-132

PubMed: 30417074 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 30038711 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 17(3):603-613

PubMed: 29237806 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1533-1542

PubMed: 28795691 ( click the link to review the publication )

Cell Signal, 2017, 29:138-149

PubMed: 27777072 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(7):473-483

PubMed: 28475408 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Anticancer Res, 2017, 37(11):6125-6132

PubMed: 29061793 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2094-104

PubMed: 26893478 ( click the link to review the publication )

Cancer Lett, 2016, 376(2):218-25

PubMed: 27060207 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Mol Imaging, 2015, 13(0):1-5

PubMed: 25248353 ( click the link to review the publication )

Chem Biol, 2015, 22(4):504-515

PubMed: 25865310 ( click the link to review the publication )
Nat Commun, 2014, 5:3116

PubMed: 24445538 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1471

PubMed: 25321478 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Liver Int, 2014, 10.1111/liv.12524

PubMed: 24621440 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

Genes Genomics, 2014, 36(6):829-841

PubMed: 25530832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7945-59

PubMed: 25277206 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e627

PubMed: 23661005 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 377(1-2):1-6

PubMed: 23811235 ( click the link to review the publication )

Surgery, 2012, 152(6):1238-47

PubMed: 23158190 ( click the link to review the publication )

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

产品描述

靶点

VEGFR2/KDR ^[1] (Cell-free assay)	c-Met ^[1] (Cell-free assay)	Axl ^[1] (Cell-free assay)
0.035 nM	1.3 nM	7 nM

体外研究

XL184是多种受体酪氨酸激酶小分子抑制剂，尤其抑制c-Met 和VEGFR2。XL-184也有效作用于Ret, Kit, FLT1, FLT3, FLT4, Tie2, 和 AXL ， IC50分别为 4 nM, 4.6 nM, 12 nM, 11.3 nM, 6 nM, 14.3 nM, 和7 nM。XL184微弱抑制 RON 和PDGFR-β，IC50分别为 124 nM和 234 nM,而对FGFR1则几乎没有抑制活性，IC50 为5.294 μM。^[1] XL184低浓度(0.1-0.5 μM) 时处理MPNST细胞，也显著抑制组成型和诱导型Met磷酸化及其下游信号，且抑制 HGF诱导的MPNST细胞迁移和侵袭。XL184作用于细胞因子刺激的人脐静脉内皮细胞（HUVECs），也显著抑制Met和VEGFR2磷酸化。虽然XL184浓度为0.1 μM时不能抑制MPNST细胞生长，但是浓度为5-10 μM 时则能显著抑制MPNST细胞生长。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
E98NT	NITL[\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjXN\|QxNjBzLUGwJO69VQ>?		NYnmcHBKTE2VTx?=	MonoTWM2OD16OTDuUS=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6NECwOkc,OjN2OESwNFY9N2F-
SNU-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPsOIIzUUN3ME2gNVkhdk1?	NFfZO5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
Hs746T	M{XxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfZeYNWUUN3ME25Mlkhdk1?	NX[5V\|Q6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
SNU-1	NX7FcpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTV{MkOgcm0>	MkDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
SNU-16	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDnO4NKSzVyPUGxOFkhdk1?	MmTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
MDA-MB-231	M2fVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LvWGlEPTB;IE[0NlEhdk1?	MljHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
U87MG	M1nIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjrUJZKSzVyPUG4OVEhdk1?	Mn2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
H441	NUDPN2U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWr6dmtLUUN3ME2yNVcxOCCwTR?=	M2K1[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
H69	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfCTWM2OD1{MEKwNEBvVQ>?	NVjURoVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
PC3	NXTSU2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfZTWM2OD1zMEiwNEBvVQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
MTC-TT	NULuSXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGi0S4VKSzVyPUCuNFQhMyByLkCzJO69VQ>?	M3[3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
MZ-CRC	NWDhdI14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zaXWlEPTB-IEWg{txO	M1HKWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
TPC-1	M1vHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nkVmlEPTB;MD6wOkAsKDBwMEKg{txO	NXrJUohNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O\|A6QTVpPkKxOFcxQTl3PD;hQi=>
NIH-3T3/TPR-Met	NXWyTppmTnWwY4Tpc44h[XO\|YYm=				NFrQZnVKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDpckBud3W\|ZTDOTWguO1R\|L2TQVk1O\XRiY3XscJMtKEmFNUCgQUAyKM7:TT6=	MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OU[xOFQoRjJ2OUm2NVQ1RC:jPh?=
BA/F3	MmTKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M2r6ZmlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIG\FS2ZTOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wLDDHTVUxKD1iMD6wNFMh\|ryPLh?=	NYDhTXpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BaF3	M3i3PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NE\kOYU1QCCqcoO=		NFP4NppKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD6wNUDPxE1w	NULvU\|ZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BA/F3	NGG5NXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUG0PEBpenN?		NISxOJNKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDUSWwu\nW\|ZXSgVmVVKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEWg{txONg>?	NFW5To49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	NEexbIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWSycoJROTBiZHH5dy=>		NVzPWGJ{UW6qaXLpeIlwdiCxZjDSSXQhSzZ\|NGegcZV1[W62IHnuJIh2dWGwIGTUJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOTBiZHH5d{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkGyJO69VS5?	Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BA/F3	NWjm[Fh{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoroOFghcHK\|		M1rVbWlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBXQDB2TTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD64PUDPxE1w	M1HndFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BaF3	NV7aOZJCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{fBUlQ5KGi{cx?=		MX7Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCUZYSgWlgxPExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC57MTFOwG0v	NWHjZoxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
Nthy-ori 3-1	M{KxZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M{TkblExKGSjeYO=		NHX1N2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPfGi7LX;ybUA{NTFiY3XscJMh[W[2ZYKgNVAh\GG7czDifUBOXFRiYYPzZZktKEeLNUCgQUA1Njl\|IN88UU4>	NVjIUm1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BAF3	NUfxbVBqTnWwY4Tpc44h[XO\|YYm=	M1nKPFAvODFidH:gNVAhfU1?	NWDuTotTOSCqch?=		MXTJcohq[mm2aX;uJI9nKFSHTD3meZNm\CC5aXzkJJR6eGViUnX0JEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIHH0JHkyODZ{L2m5NFUh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYSgNE4xOSC2bzCxNEB2VSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NGXrd2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	MojTSpVv[3Srb36gZZN{[Xl?		NHX2V\|Y1KGi{cx?=		NVuzdZR6UW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUmwOUBqdiCqdX3hckBVXCClZXzsd{BifCBzIIXNJIFnfGW{IESgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MnTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3	MojwSpVv[3Srb36gZZN{[Xl?	NEXleG8xNjBzIITvJFExKHWP	NGmydlgyKGi{		MVzJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCUZYSgV\|g6OUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkheGixc4Doc5J6dGG2aX;uJIF1KFlzME[yM3k6ODViZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZQhOC5yMTD0c{AyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NWG4e4N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BAF3	NXv6OZFuTnWwY4Tpc44h[XO\|YYm=	NHe0VI0xNjBzIITvJFExKHWP	MUixJIhz		M2\lfWlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBUQDlzQTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDwbI9{eGixconsZZRqd25ib3[gVGxE\2GvbXGgZZQhYTd6MzDheEAxNjBzIITvJFExKHWPIHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	Mn\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3	NYXZZpEzTnWwY4Tpc44h[XO\|YYm=	MlvhNE4xOSC2bzCxNEB2VQ>?	NXnTdmcyOSCqch?=		NUfme\|h7UW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgVoV1KFN6OUHBJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGmxbjDv[kBUcGNiYYSgXVMyPyCjdDCwMlAyKHSxIEGwJJVOKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	NYrB[W1rTnWwY4Tpc44h[XO\|YYm=	NVzmXoJyOSC2bzCxNEB2VQ>?	MXK0JIhzew>?		NUXCeHlHUW6qaXLpeIlwdiCxZjDSSXQhSzZ\|NGegcZV1[W62IHnuJIh2dWGwIGTUJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIGDMR4didW2jIIDoc5NxcG:{eXzheIlwdiCjdDDZO\|g{KGG2IEGgeI8hOTBidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M3\YNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT	MWPGeY5kfGmxbjDhd5NigQ>?	MYGxJJRwKDFyIIXN	NEPSTY01KGi{cx?=		NFjUUmFKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVOjB{L2myNFQh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	MnTSSpVv[3Srb36gZZN{[Xl?	NHKwOmYyKHSxIEGwJJVO	NUHmb5h5PCCqcoO=		MW\Jcohq[mm2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQhcW5iaIXtZY4hXFRiY3XscJMh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUN\|A5N1N2N{OgZZQhOSC2bzCxNEB2VSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M1ey[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT	MlfCSpVv[3Srb36gZZN{[Xl?	NWO0RWplOSC3TR?=			NUHvRlJiUW6qaXLpeIlwdiCxZjDS[ZQu\HKrdnXuJI9v[2:pZX7pZ{B1emGwc3\vdo1ifGmxbjDv[kBpfW2jbjDUWEBk\WyuczDheEAyKHWPIHL5JJNw\nRiYXfhdkBie3OjeR?=	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT	MUfGeY5kfGmxbjDhd5NigQ>?	MVOxJJVO	MUm0JIhzew>?		MXHJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gVmVVKEN4M{TXJI12fGGwdDDheEB[OTB4MjDpckBpfW2jbjDUWEBk\WyuczDheEAyKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	Mo[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT	NHT5folCeG:ydH;zbZMh[XO\|YYm=	NFvaR4cyKHWP	NVfLV4s1QTZiaILz		M4jpNmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iVGSgZ4VtdHNiZYjwdoV{e2mwZzDS[ZQhSzZ\|NGegcZV1[W62IHH0JFEhfU1iYX\0[ZIhQTZiaILzJIJ6KGGwbnX4bY5XN1CLIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=>	NWGzfIduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
PC3	MV3GeY5kfGmxbjDhd5NigQ>?		M1vPSlEhfG9iMzDodpM>		NWDxOGdPUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hWEN\|IHPlcIx{KGmwY4XiZZRm\CCob4KgNUB1dyB\|IHjyd{whUUN3MDC9JFEvQSEQvF2u	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
MDA-MB-231	MYPGeY5kfGmxbjDhd5NigQ>?		MkT2NUB1dyB\|IHjydy=>		NYTRU\|hDUW6qaXLpeIlwdiCxZjDBXGwheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgbY5kfWKjdHXkJIZweiBzIITvJFMhcHK\|LDDJR\|UxKD1iNTFOwG0v	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
BAF3	NVHNV4tpTnWwY4Tpc44h[XO\|YYm=		MonyNUB1dyB\|IHjydy=>		M1;i[mlvcGmkaYTpc44hd2ZiRlzUN{ApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGmwY4XiZZRm\CCob4KgNUB1dyB\|IHjyd{whUUN3MDC9JFcvPSEQvF2u	MkLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
MDA-MB-231	M{T2cmZ2dmO2aX;uJIF{e2G7		MnjQNUB1dyB\|IHjydy=>		M13SdWlvcGmkaYTpc44hd2ZiS1nUJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIITyZY5{\mWldHXkJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgbY5kfWKjdHXkJIZweiBzIITvJFMhcHK\|LDDJR\|UxKD1iNEKg{txONg>?	M1n6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{G3NlAyLz5{NkexO\|IxOTxxYU6=
BA/F3	MX;GeY5kfGmxbjDhd5NigQ>?		M4fifVQ5KGi{cx?=		NVyx[pVuUW6qaXLpeIlwdiCxZjDLSHIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDD[YxtKHSrdILlJIdtdy2kYYPl[EBtfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjBzNDFOwG0v	Mnq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O\|QyRC:jPh?=
Sf21	M{KyWmZ2dmO2aX;uJIF{e2G7		MlLQNVUhdWmwcx?=		Mn[wTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO\|YYmsJGlEPTBiPTCwMlAyPiEQvF2u	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O\|QyRC:jPh?=
BA/F3	NGDHcINHfW6ldHnvckBie3OjeR?=		MlnOOFghcHK\|		MVHJcohq[mm2aX;uJI9nKEuLRkXCM3JGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGNmdGxidHn0doUh\2yxLXLhd4VlKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUmg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3	NE[4cYxHfW6ldHnvckBie3OjeR?=		MWS0PEBpenN?		M1rJUmlvcGmkaYTpc44hd2ZiS1nGOWIwWkWWIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhS2WubDD0bZRz\SCpbH:tZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6xPUDPxE1w	M3njNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O\|QyLz5{Nki3OFc1OTxxYU6=
BA/F3	MmXlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX\BfolDPzJiaILz		NFL6UmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXFCULV3leEBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODJzOTFOwG0v	M1T4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[4PFg6Lz5{N{C2PFg5QTxxYU6=
Sf21	M133OGZ2dmO2aX;uJIF{e2G7		NIDNbJM3OCCvaX7z		Ml\GTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHJGXCBqNkW4JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNidYPpcocheG:ueTjHcJUtXHm{KUS6NUBieyC\|dXLzeJJifGViaX7jeYJifGWmIH\vdkA3OCCvaX7zJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODNizszNMi=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Sf21	MoL4SpVv[3Srb36gZZN{[Xl?		M2n6dlYxKG2rboO=		Mlu0TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gVmVVKFZ6METNJI12fGGwdDCoOlU5KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmNlEh[2WubIOgeZNqdmdicH;sfUhIdHVuVInyLVQ7OSCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB4MDDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOC56MUGg{txONg>?	NETzRYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
BaF3	NVz2c5VYTnWwY4Tpc44h[XO\|YYm=		M1X1TVczKGi{cx?=		NVWwepRjUW6qaXLpeIlwdiCxZjDDR2REPi2URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoFHOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR\|UxKD1iMD64PFkh\|ryPLh?=	NIjsS289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
BaF3	NGjoRlNHfW6ldHnvckBie3OjeR?=		NYTnVpk3PzJiaILz		M{LLb2lvcGmkaYTpc44hd2ZiQ1PER\|YuWkWWIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwOEi5JO69VS5?	MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Ba/F3	MkLESpVv[3Srb36gZZN{[Xl?				NXnjW\|gzUW6qaXLpeIlwdiCxZjDSSXQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjB5IN88UU4>	M1fpXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
TT	NUTyc246TnWwY4Tpc44h[XO\|YYm=				MYLJcohq[mm2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQhcW5iaIXtZY4hXFRiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDHTVUxKD1iMD6yOkDPxE1w	M{HpZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
Ba/F3	NIj2ZZNHfW6ldHnvckBie3OjeR?=				M1fqVmlvcGmkaYTpc44hd2ZiUlXUJHY5ODSPIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>?	M4HtW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
Nthy-ori 3-1	NYfuUHBNS3m2b4TvfIlkcXS7IHHzd4F6				MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOeIh6NW:{aTCzMVEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCJSUWwJF0hOi57MjFOwG0v	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUS1OlAoRjJ5OEG0OVYxRC:jPh?=
HepG2	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIHOXoU4OiCqcoO=		NWjCU3ZSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOTJizszNMi=>	NYrWT\|dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
EBC1	NHHGR3dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWf4e\|JkPzJiaILz		MojmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCHQlOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC1NVQh\|ryPLh?=	NUX5VXB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
H1299	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVK3NkBpenN?		MX\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDINVI6QSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNU46OTlizszNMi=>	M2ruUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
MCF7	NF7MOGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF7ifZI4OiCqcoO=		M{TmXmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFIvQDh7IN88UU4>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
A549	NV\1XWpFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1ezV\|czKGi{cx?=		MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTC0MlIxPSEQvF2u	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
T47D	NXi4Tll{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYG3NkBpenN?		MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDUOFdFKGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTC0MlQ1QCEQvF2u	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
H460	M364WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIfRSGU4OiCqcoO=		MnPaS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTFQ3OCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gOU43PjlizszNMi=>	NHfzNG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[1NVk4QSd-Mki2OVE6Pzl:L3G+
HuH7	MkToRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV[0PEBpenN?		M3;RemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND6zOFgh\|ryPLh?=	Mn7kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyNUewOFIoRjJ7MEW3NFQzRC:jPh?=
A498	NUX5[5NESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVS0PEBpenN?		NILGUmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEiuOFU3KM7:TT6=	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyNUewOFIoRjJ7MEW3NFQzRC:jPh?=
NCI-H727	MmDwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWG0PEBpenN?		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IO\|I4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOE4xOSEQvF2u	NVLPflNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
BAF3	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2HmTlczKGi{cx?=		M4HrfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegWHJRNU2HVDDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAzPCEQvF2u	NGqybWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlQ2Oid-MkmxOFY1PTJ:L3G+
A549	NIW5U2dEgXSxdH;4bYNqfHliYYPzZZk>	M4[2XFExKHWP	M2HPNFczKGi{cx?=		MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF1KDFyIIXNJIFnfGW{IEeyJIhzeyCkeTDJcoN2[3m2ZTDsbZZmNWOnbHygbY1i\2mwZzDhcoFtgXOrcx?=	MkTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OlMoRjJ7NEC3PVY{RC:jPh?=
A673	M1mycZFJXFNiYYPzZZk>				M{fXZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MlfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NHfOOYRyUFSVIHHzd4F6				NXflO29IeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	MlnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NHzUbZdyUFSVIHHzd4F6				MkL4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	NHizVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	M1vHNJFJXFNiYYPzZZk>				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	NITvZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MXXxTHRUKGG\|c3H5				Mn\qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M1vuZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MoHYdWhVWyCjc4PhfS=>				MkS0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NWHYdnp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MXfxTHRUKGG\|c3H5				MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NFy4eGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NV3EWJJjeUiWUzDhd5NigQ>?				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	M2PrN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	M1jRTZFJXFNiYYPzZZk>				MkXJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	M3HsflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MUHxTHRUKGG\|c3H5				MlT3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M4P3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MV\xTHRUKGG\|c3H5				NIDYToVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NXnv[o9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	M3zMNZFJXFNiYYPzZZk>				NW\NWIVDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NEPVVWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NUT1TZFTeUiWUzDhd5NigQ>?				NYW1NVZDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NE\tS3ByUFSVIHHzd4F6				MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NEn3[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NWe3TJVYeUiWUzDhd5NigQ>?				NUXqdJVZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NX:wN\|BJeUiWUzDhd5NigQ>?				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MlPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M2nSNZFJXFNiYYPzZZk>				M2npdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M2DkSpFJXFNiYYPzZZk>				NXfCbWg6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M4\sNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NWW0bIZzeUiWUzDhd5NigQ>?				MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NFzCS2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MYnxTHRUKGG\|c3H5				MmnGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	NX7kWWRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	Ml;FdWhVWyCjc4PhfS=>				MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	NXfHRZp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MkHmdWhVWyCjc4PhfS=>				NXHveIsyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NYDrbJlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
EBC1	NUT5UXV4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIfreHA4OiCqcoO=		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEC0PEDPxE1w	MnjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
MKN45	NUfsclR5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYTlOY1PPzJiaILz		MkDDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPS160OUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFY6KM7:TT6=	NWDYPHJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFg3PTRpPkOwNlQ5PjV2PD;hQi=>
SNU5	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYq3NkBpenN?		NXK1Z4M5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUnU2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAyOjFizszNMi=>	NHv4SFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
BAF3	NGjvOYNHfW6ldHnvckBie3OjeR?=		M{jPTVczKGi{cx?=		NHz5WVJKdmirYnn0bY9vKG:oIGTQVk11[WepZXSgcYV1KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEG5PFYh\|ryPLh?=	NFHNflI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
NCI-H460	M{TLfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXu3NkBpenN?		MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA1ODFizszNMi=>	M1zYdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5\|MEK0PFY2PDxxYU6=
MGHU3	NF\yV5dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUG3NkBpenN?		NWr1dolOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2hWOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfS=>	NYmxVXNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzNFk3PzFpPkOwN\|A6PjdzPD;hQi=>
RT112	M2XQPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVG3NkBpenN?		MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7	NGLpPJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEOwPVY4OSd-M{CzNFk3PzF:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; PubMed: 29188469 Invest New Drugs MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM. p-MET / p-ERK / p-AKT; PubMed: 29520051 Sci Rep Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.	29188469 29520051
Immunofluorescence	α-tubulin; PubMed: 29520051 Sci Rep Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.	29520051
Growth inhibition assay	Cell viability; PubMed: 23661005 Cell Death Dis Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.	23661005

体内研究

XL184按 30 mg/kg 剂量处理携带自发胰岛细胞瘤的RIP-Tag2 小鼠，扰乱 83%肿瘤血管, 降低周细胞和空基底膜袖，引起广泛瘤内缺氧和广泛的肿瘤细胞凋亡，且停药后延缓肿瘤血管再生长，与XL999相比更显著抑制VEGFR而不是c-Met，导致血管降低43％，说明抑制VEGFR，也抑制放大抑制血管新生的其他功能相关的受体酪氨酸激酶（RTK）。XL184也降低原发肿瘤的侵袭和减少转移。^[1] XL184 每天按30 mg/kg剂量处理SCID小鼠，显著废除人 MPNST移植瘤生长和转移。^[2] XL184 处理乳腺癌，肺癌胶质瘤模型，抑制肿瘤生长，这种作用存在剂量依赖性，降低肿瘤和内皮细胞增殖，促进凋亡。XL184按100 mg/kg 和 10 mg/kg剂量分别单独处理携带MDA-MB-231肿瘤的小鼠和携带C6肿瘤的大鼠，持续抑制肿瘤生长。^[3]

细胞实验： ^[2]	- 合并 Cell lines: ST88-14, STS26T, 和MPNST724 Concentrations: 溶于DMSO,终浓度~10 μM Incubation Time: 48小时 Method: 使用不同浓度XL184处理细胞48小时。通过MTS实验使用CellTiter96 Aqueous 非放射性细胞增殖实验试剂盒测定细胞生长。然后在 490 nm处测定吸光值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带自发胰岛肿瘤的RIP-TAG2转基因小鼠。 Dosages: ~60 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (199.39 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cabozantinib (BMS-907351) SDF

分子量	501.51
化学式	C₂₈H₂₄FN₃O₅
CAS号	849217-68-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	XL184

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04631744	Not yet recruiting	Drug: Cabozantinib	Prostate Cancer	Weill Medical College of Cornell University\|Exelixis	February 15 2021	Phase 2
NCT04551430	Not yet recruiting	Drug: Cabozantinib\|Drug: Nivolumab\|Drug: Ipilimumab	Metastatic Soft-tissue Sarcoma	Washington University School of Medicine\|Exelixis\|Bristol-Myers Squibb	December 31 2020	Phase 2
NCT04524208	Not yet recruiting	Drug: Cabozantinib	Neuroendocrine Tumors\|Neuroendocrine Carcinoma	Karsten Gavenis\|University Medical Center Goettingen	December 1 2020	Phase 2
NCT04300140	Recruiting	Drug: AVB-S6-500\|Drug: Cabozantinib (Cabo)	Clear Cell Renal Cell Carcinoma	Aravive Inc.	December 2020	Phase 1\|Phase 2
NCT04637204	Recruiting	Drug: Cabozantinib\|Drug: Axitinib	Renal Cell Carcinoma	Ipsen	November 24 2020	--
NCT04609800	Withdrawn	--	Renal Cell Carcinoma	Ipsen	November 6 2020	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

泛VEGFR抑制剂

Regorafenib (BAY 73-4506) : Pan-VEGFR inhibitor, VEGFR1/VEGFR2/VEGFR3, IC50=13 nM/4.2 nM/46 nM.
活性最高的VEGFR抑制剂

Axitinib : VEGFR1, VEGFR2, VEGFR3, IC50=0.1 nM, 0.2 nM, 0.1-0.3 nM.
FDA批准的VEGFR抑制剂

Axitinib : Approved by FDA for Renal Cell Carcinoma.
经典的VEGFR抑制剂

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

研究领域

产品类型

定制您的化合物库

Cabozantinib (BMS-907351)

客户使用Selleck生产的Cabozantinib (BMS-907351)发表文献83篇：

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cabozantinib (BMS-907351) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

相关VEGFR产品